🎉 M&A multiples are live!
Check it out!

AIM Vaccine Valuation Multiples

Discover revenue and EBITDA valuation multiples for AIM Vaccine and similar public comparables like AstraZeneca India, GSK India, and Prescient Therapeutics.

AIM Vaccine Overview

About AIM Vaccine

AIM Vaccine Co Ltd is a top full-chain vaccine corporation in China with businesses covering the whole industrial chain ranging from research and development to manufacturing and commercialization. The Vaccine products include Recombinant HBV Vaccines, Freeze-dried Human Rabies Vaccine, Inactivated HAV Vaccines, Group A, C, Y, and W135 MPSV, Bivalent Inactivated HFRS Vaccine, and Mumps Vaccine. It generates all of its revenues in the PRC.


Founded

2011

HQ

Hong Kong
Employees

1.6K+

Website

aimbio.com

Financials

LTM Revenue $197M

LTM EBITDA n/a

EV

$707M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

AIM Vaccine Financials

AIM Vaccine has a last 12-month revenue of $197M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, AIM Vaccine achieved revenue of $153M and an EBITDA of -$264M.

AIM Vaccine expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See AIM Vaccine valuation multiples based on analyst estimates

AIM Vaccine P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $163M $153M XXX XXX XXX
Gross Profit $167M $132M XXX XXX XXX
Gross Margin 102% 87% XXX XXX XXX
EBITDA -$31.1M -$264M XXX XXX XXX
EBITDA Margin -19% -173% XXX XXX XXX
Net Profit -$89.1M -$41.1M XXX XXX XXX
Net Margin -55% -27% XXX XXX XXX
Net Debt n/a $91.9M XXX XXX XXX

Financial data powered by Morningstar, Inc.

AIM Vaccine Stock Performance

As of April 15, 2025, AIM Vaccine's stock price is HKD 3 (or $0).

AIM Vaccine has current market cap of HKD 4.2B (or $536M), and EV of HKD 5.5B (or $707M).

See AIM Vaccine trading valuation data

AIM Vaccine Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$707M $536M XXX XXX XXX XXX $-0.02

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

AIM Vaccine Valuation Multiples

As of April 15, 2025, AIM Vaccine has market cap of $536M and EV of $707M.

AIM Vaccine's trades at 3.8x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate AIM Vaccine's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for AIM Vaccine and 10K+ public comps

AIM Vaccine Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $707M XXX XXX XXX
EV/Revenue 4.6x XXX XXX XXX
EV/EBITDA -2.7x XXX XXX XXX
P/E -3.2x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -11.8x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get AIM Vaccine Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

AIM Vaccine Valuation Multiples

AIM Vaccine's NTM/LTM revenue growth is 59%

AIM Vaccine's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.1M for the same period.

Over next 12 months, AIM Vaccine's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate AIM Vaccine's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for AIM Vaccine and other 10K+ public comps

AIM Vaccine Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -6% XXX XXX XXX XXX
EBITDA Margin -173% XXX XXX XXX XXX
EBITDA Growth 748% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -114% XXX XXX XXX XXX
Revenue per Employee $0.1M XXX XXX XXX XXX
Opex per Employee $0.1M XXX XXX XXX XXX
S&M Expenses to Revenue 42% XXX XXX XXX XXX
G&A Expenses to Revenue 21% XXX XXX XXX XXX
R&D Expenses to Revenue 54% XXX XXX XXX XXX
Opex to Revenue 114% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

AIM Vaccine Public Comps

See public comps and valuation multiples for Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
CSL XXX XXX XXX XXX XXX XXX
Imugene XXX XXX XXX XXX XXX XXX
Prescient Therapeutics XXX XXX XXX XXX XXX XXX
GSK India XXX XXX XXX XXX XXX XXX
AstraZeneca India XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

AIM Vaccine M&A and Investment Activity

AIM Vaccine acquired  XXX companies to date.

Last acquisition by AIM Vaccine was  XXXXXXXX, XXXXX XXXXX XXXXXX . AIM Vaccine acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by AIM Vaccine

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About AIM Vaccine

When was AIM Vaccine founded? AIM Vaccine was founded in 2011.
Where is AIM Vaccine headquartered? AIM Vaccine is headquartered in Hong Kong.
How many employees does AIM Vaccine have? As of today, AIM Vaccine has 1.6K+ employees.
Who is the CEO of AIM Vaccine? AIM Vaccine's CEO is Mr. Yan Zhou.
Is AIM Vaccine publicy listed? Yes, AIM Vaccine is a public company listed on HKG.
What is the stock symbol of AIM Vaccine? AIM Vaccine trades under 06660 ticker.
When did AIM Vaccine go public? AIM Vaccine went public in 2022.
Who are competitors of AIM Vaccine? Similar companies to AIM Vaccine include e.g. CSL, Imugene, Prescient Therapeutics, GSK India.
What is the current market cap of AIM Vaccine? AIM Vaccine's current market cap is $536M
What is the current revenue of AIM Vaccine? AIM Vaccine's last 12-month revenue is $197M.
What is the current EV/Revenue multiple of AIM Vaccine? Current revenue multiple of AIM Vaccine is 3.8x.
What is the current revenue growth of AIM Vaccine? AIM Vaccine revenue growth between 2023 and 2024 was -6%.
Is AIM Vaccine profitable? Yes, AIM Vaccine is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.